Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene metabolic effects in hypogonadal men
ACTRN12608000537358Phase 4Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of raloxifene in Hypoandrogenism (TD) and prostate cancer (PCa) (2 arms), sponsored by St Vincent's Hospital. Primary endpoint: Growth hormone secretion after arginine stimulation. Started Feb 2008; status: recruiting.
02
Drugs
raloxifene
03
Conditions
Hypoandrogenism (TD)prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12608000537358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000537358.